EUVIMEDEUVIMED entdecken
Crossref

Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis

Neha Yadav, Sumeet P Mirgh, Mukul Aggarwal, Narendra Agrawal, Pallavi Mehta, Vishvdeep Khushoo, Jyotsna Kapoor, Niharika Bhatia, Pragya Agrawal, Rayaz Ahmed, Dinesh Bhurani

Indian Journal of Cancer · 2023

DOI: 10.4103/ijc.ijc_272_21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Cancer, 2023. Verfasst von Neha Yadav und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and BMT Unit, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, Delhi, India. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Heterocyclic Compounds, Multiple Myeloma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple myeloma remains an incurable disease, with the majority of patients relapsing after autologous stem cell transplant (ASCT). After relapse, second transplant remains one of the therapeutic options, along with novel agents.

Methods

We reviewed the data of our patients who underwent ASCT for myeloma ( N = 202) over the last two decades (2004–2019). Of these, 12 patients underwent a second transplant.

Results

Out of 12 patients, nine underwent second autologous stem cell transplant, whereas three received an allogeneic stem cell transplantation (Allo-SCT). Median progression-free survival (PFS) after the first ASCT was 32 months (5–84 months). Median interval between both the transplants was 35 months (4–159 months). Median age of our cohort which underwent second transplant was 56 years. Overall response rate (ORR) post-second transplant on day +100 was 83.3%, without any transplant-related mortality (TRM). With the use of preemptive plerixafor, none of our patients required a second day for stem cell harvest. Median CD34 dose of stem cells infused was 4.11 × 10 6 /kg. Similar to the first ASCT, the median time to neutrophil and platelet engraftment was 11 and 12 days, respectively. At a median follow-up of 41 months, estimated 3-year PFS and overall survival (OS) was 37% ± 15% and 63% ± 15%, respectively.

Conclusion

Among all relapsed myeloma patients who were transplant eligible, 11% underwent a second transplant. Second transplant is well tolerated with similar time to engraftment after first ASCT. Hence, we believe that second transplant is a feasible, cost-effective option in a resource-limited setting, which should be more widely utilized.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHeterocyclic CompoundsMultiple MyelomaHumansMiddle AgedHematopoietic Stem Cell MobilizationRetrospective StudiesStem Cell TransplantationTransplantation, AutologousTreatment Outcome

Stichwörter der Autor:innen

Allogeneic Hematopoietic Stem Cell Transplantationautologous hematopoietic stem cell transplantationmultiple myelomaoverall survivalprogression-free survivalsecond hematopoietic stem cell transplantation

Substanzen

Heterocyclic Compounds

Autor:innen und Institutionen

  • Department of Hematology and BMT Unit, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, Delhi, India.
  • Department of Hematology and BMT Unit, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, Delhi; Adult Hematolymphoid and BMT Unit, Tata Memorial Centre, ACTREC, Mumbai, Maharashtra, India (Present Aff…

Zitieren

APA

Yadav, N., Mirgh, S. P., Aggarwal, M., Agrawal, N., Mehta, P., Khushoo, V., Kapoor, J., Bhatia, N., Agrawal, P., Ahmed, R., & Bhurani, D. (2023). Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_272_21

Vancouver

Yadav N, Mirgh SP, Aggarwal M, Agrawal N, Mehta P, Khushoo V, et al. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis. Indian Journal of Cancer. 2023. doi:10.4103/ijc.ijc_272_21

BibTeX
@article{Yadav2023,
  author = {Yadav, Neha and Mirgh, Sumeet P and Aggarwal, Mukul and Agrawal, Narendra and Mehta, Pallavi and Khushoo, Vishvdeep and Kapoor, Jyotsna and Bhatia, Niharika and Agrawal, Pragya and Ahmed, Rayaz and Bhurani, Dinesh},
  title = {Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis},
  journal = {Indian Journal of Cancer},
  year = {2023},
  doi = {10.4103/ijc.ijc_272_21}
}
Kostenlos starten →